This is a Phase III study to help us improve outcomes of patients with ER+/HER2- early breast cancer with intermediate or high risk for disease recurrence. This study is for patients who have completed definitive locoregional therapy and standard adjuvant endocrine therapy for at least 2 years and up to 5 years without disease recurrence. In this study, we want to learn if a new oral "SERD" therapy called Camizestrant is helpful in reducing chance of recurrence. Talk to your Medical Oncologist for more information about this trial.
You will meet with a member of the study team at each visit. Your study doctor will closely monitor your health while you are participating in the study. You will be assigned randomly to one of 2 arms of the trial. You have a 50% chance of receiving the study drug (Camizestrant). If you don't receive the study drug, you may remain on your current endocrine therapy. This is not a "blinded study." You and your doctor will know which treatment you are on. During the study, you will have several EKG's, ophthalmology visits, vital signs, and blood tests. You will not pay for any of the study procedures, including the study drug or your usual hormonal therapy.
Mileage reimbursement from your home address if more than 25 miles from the study clinic. Study medication and study procedures at no cost.
UNC Rex Cancer Center
2901 Blue Ridge Rd, Raleigh, NC 27607, USA
Jayadev Manikkam Umakanthan
UNC Hospitals - Rex
Clinical or Medical
Interventional
Cancer (Breast)
23-0429
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
